TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Chemtura Corp (NYSE:CHMT) Investor Lawsuit Against Acquistion By LANXESS AG

  • If you purchased shares of Chemtura Corp (NYSE:CHMT) and currently hold any of those NYSE:CHMT shares, you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Company
Chemtura Corp
Security
NYSE: CHMT

Case Name
Chemtura Deal Case 12/30/2016
Type of Lawsuit
Mergers and Acquisition
You must register or login to receive notifications.

Click here to subscribe to Chemtura Corp.
Summary

December 30, 2016 (Shareholders Foundation) - An investor who currently holds shares of Chemtura Corp (NYSE:CHMT), filed a lawsuit in effort to halt the proposed takeover of Chemtura Corp. by LANXESS AG for $33.50 per share.
The plaintiff alleges that the defendants breached their fiduciary duties owed to NYSE:CHMT stockholders by agreeing to sell Chemtura Corp. too cheaply via an unfair process to LANXESS AG.

On September 25, 2016, Chemtura Corp (NYSE:CHMT) announced that it has entered into an agreement pursuant to which LANXESS AG will acquire Chemtura Corp (NYSE:CHMT) in a transaction valued at approximately $2.5 billion. Under the terms of the agreement, Chemtura Corp (NYSE:CHMT) shareholders will receive $33.50 per share in cash for each outstanding share of common stock held.

However, plaintiff claims that the proposed consideration NYSE:CHMT shareholders will receive is grossly inadequate and undervalues Chemtura Corp. Indeed, at least one analyst has set the high target price for NYSE:CHMT shares at $35.00 per share. In addition, the plaintiff alleges that the process is also unfair NYSE:CHMT stockholders.